Comparison of Single-Dose Toxicity by Intravenous Infusion or Bolus Injection with CKD-602, a Camptothecin Anticancer Agent in Rats (I): Toxic Effects with regard to Mortality and Clinical Signs |
Kim, Choong-Yong
(Korea Institute of Toxicology)
Han, Junghee (Korea Institute of Toxicology) Yang, Byung-Chul (Korea Institute of Toxicology) Kim, Joon-Kyum (Medicinal Research Center, Chong Kun Dang Co.) Kim, Jong-Choon (College of Veterinary Medicine, Chonnam National University) Ha, Chang-Su (Korea Institute of Toxicology) Han, Sang-Seop (Korea Institute of Toxicology) |
1 | Edelman, E.R. and Karnovsky, M.J. (1994): Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis. Circulation, 89, 770-776 DOI PUBMED |
2 | Flynn, J.L., Chan, J., Triebold, KJ., Dalton, O.K., Stewart, T.A. and Bloom, B.R. (1993): An essential role for interferon gamma in resistance to mycobacterium tuberculosis infection. Journal of Experimental Medicine, 178, 2249-2254 DOI |
3 | Gargosky, S.E., Tapanainen, P. and Rosenfeld, R.G. (1994): Administration of growth hormone (GH), but not insulinlike growth tactor-t (IGF-I), by continuous infection can induced the formation of the 150-kilodalton IGF-binding protein-3 complex in GH-deficient rats. Endocrinology, 134, 2267-2276 DOI PUBMED ScienceOn |
4 | Moertel, C.G., Schutt, A.J., Reitmeier, R.J. and Hahn, R.G. (1972): Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 56, 95-101 |
5 | Pizzolato, J.F. and Saltz, L.B. (2003): The camptothecins.Lancet, 361, 2235-2242 |
6 | Takimoto, C.H., Wright, J. and Arbuck, S.G. (1998): Clinical applications of the camptothecins. Biochim. Biophys. Acta, 1400, 107-119 |
7 | Lee, J.H., Lee, J.M., Kim, J.K., Ahn, S.K., Lee, S.J., Kim, M.Y., Jew, S.S., Park, J.G. and Hong, C.I. (1998): Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)- camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch. Pharm. Res., 21, 581-590. |
8 | Evans, J.G. and Kerry, P.J. (2000): Common pathological findings in continuous infusion studies. In: Guy healing and David Smith (eds.) Handbook of preclinical continuous intravenous infusion. Taylor & Francis, pp 253-264 |
9 | Dahut, W., Harolod, N., Takimototo, C., Allegra, C., Chen, A., Hamilton, J.M., Arbuck, S., Sorensen, M., Grollman, F., Nakashima, H., Lieberman, R., Liang, M., Corse, Wand Grem, J. (1996): Phase I and pharmacokinetic study of 9aminocamptothecin given as a 72-hour infusion in adult cancer patients. J. Clin. Oncol., 14, 1236-1244 |
10 | Kolimannsberger, C., Mross, K, Jakob, A, Kanz, L. and Bokemyer, C. (1999): Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience. Oncology, 56, 1-12 DOI ScienceOn |
11 | Schaeppi, U., Fleischman, E.w. and Cooney, D.A. (1974): Toxicity of Camptothecin (NSC-100880). Cancer Chemother Rep., 5, 25-3 |
12 | Hertzberg, R.P., Caranta, M.J., Holden, KG., Jakas, D.R., Gallagher, G., Mattern, M.R., Mong, S.M., Bartus, J.D., Johnson, R.K. and KingsbUry, WD. (1989): Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J. Med. Chern., 32, 715-720 |
13 | Thompson, J., Stewart, C.F. and Houghton, PJ. (1998): Animal models for studying the action of topoisomerase I targeted drugs. Biochim. Biophys Acta, 1400, 301-319 DOI |
14 | Kim, C.-Y., Imai, Y., Itoi, K, Hashimoto, J., Nobunaga, T., Satoh, H. and Abe, K. (1996): Analysis of circadian variation of blood pressure and heart rate in dexamethasoninduced hypertensive rats. Clin. Exper. Hypertension, 18, 65-76 |
15 | Tomas, F.M., Lemmey, A.B., Read, L.C. and Ballard, F.J. (1996): Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection. J. of Endocrinology, 150, 77-84 DOI ScienceOn |
16 | Jung, L.L. and Zamboni, WC. (2001): Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it? Drug Resistance Updates, 4, 273-288 |
17 | Gottlieb, J.A., Guarino, A.M., Call, J.B., Oliverio, V.T. and Block, J.B. (1970): Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother. Rep., 54, 461-470 |
18 | Wall, ME, Wani, M.C. and Cook, C.E. (1966): Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 88, 388-3890 |
19 | Bleiberg, H. and Rothenberg, M.L. (1996): CPT-11: From DNA topology to clinical activity. Semi. Oncol., 23, 1-50 |
20 | Slichenmyer, w.J. and Rowinsky, E.K. (1993): The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85, 271-291 DOI PUBMED |
![]() |